|
|
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
|
|
|
|
Summary ToggleOpiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
|
|
|
|
Summary ToggleOpiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
|
|
